HRP20191051T1 - Antitijela protiv csf-1r - Google Patents
Antitijela protiv csf-1r Download PDFInfo
- Publication number
- HRP20191051T1 HRP20191051T1 HRP20191051TT HRP20191051T HRP20191051T1 HR P20191051 T1 HRP20191051 T1 HR P20191051T1 HR P20191051T T HRP20191051T T HR P20191051TT HR P20191051 T HRP20191051 T HR P20191051T HR P20191051 T1 HRP20191051 T1 HR P20191051T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- fibrosis
- antibody
- csf
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 238000010367 cloning Methods 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 206010058029 Arthrofibrosis Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003140 astrocytic effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Claims (13)
1. Anti-CSF-1R antitijelo koje ima teški lanac naznačeno time da sadrži sekvencu danu u SEK ID BR: 27 i laki lanac koji sadrži sekvencu danu u SEK ID BR: 19.
2. Anti-CSF-1R antitijelo prema patentnom zahtjevu 1 naznačeno time da ima efektor ili molekulu reportera pripojenu na njega.
3. Anti-CSF-1R antitijelo prema patentnom zahtjevu 1 ili 2 naznačeno time da ima afinitet vezanja za ljudski CSF-1R od 10 pM ili manji od 10 pM.
4. Izolirana sekvenca DNK naznačena time da kodira teški i laki lanac(e) antitijela prema bilo kojem od patentnih zahtjeva od 1 do 3.
5. Vektor kloniranja ili ekspresije naznačen time da sadrži jednu ili više sekvenci DNK prema patentnom zahtjevu 4.
6. Vektor prema patentnom zahtjevu 5 naznačen time da vektor sadrži sekvence dane u SEK ID BR:28 i SEK ID BR:20.
7. Stanica domaćina naznačena time da sadrži jedan ili više vektora za kloniranje ili ekspresiju prema patentnom zahtjevu 6.
8. Postupak za izradu antitijela prema bilo kojem od patentnih zahtjeva od 1 do 3 naznačen time da sadrži kultiviranje stanice domaćina prema patentnom zahtjevu 7 i izoliranje antitijela.
9. Farmaceutski pripravak koji sadrži antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 3, u kombinaciji sa jednim ili više farmaceutski prihvatljivim ekscipientom, otapalom ili nosačem; naznačen time da farmaceutski pripravak sadrži po izboru sadrži druge aktivne sastojke.
10. Antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 3 ili pripravak prema patentnom zahtjevu 11, naznačeno time da je za upotrebu kao lijek.
11. Antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 3 ili pripravak prema patentnom zahtjevu 11 naznačen time da je za liječenje ili profilaksu raka ili fibrozne bolesti.
12. Antitijelo za upotrebu prema patentnom zahtjevu 11 naznačeno time da je rak odabran iz skupine koja se sastoji od raka dojke, raka prostate, raka kostiju, kolorektalnog raka, leukemije, limfoma, raka kože, raka jednjaka, raka želuca, astrocitnog raka, raka endometrijuma, raka vrata materice, raka mokraćnog mjehura, raka bubrega, raka pluća, raka jetre, raka štitnjače, raka glave i vrata, raka gušterače i raka jajnika.
13. Antitijelo za upotrebu prema patentnom zahtjevu 11 naznačeno time da je fibrozna bolest odabrana iz skupine koja se sastoji od fibroze pluća kao što je idiopatska fibroza pluća i cistična fibroza, fibroza bubrega, ciroza jetre, endomiokardijalna fibroza, medijastinalna fibroza, mijelofibroza, retroperitonealna fibroza, progresivna masivna fibroza, nefrogena sistemska fibroza, Chron-ova bolest, keloid, infarkt miokarda, sklerodermija i artrofibroza.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1315487.7A GB201315487D0 (en) | 2013-08-30 | 2013-08-30 | Antibodies |
| PCT/EP2014/068050 WO2015028455A1 (en) | 2013-08-30 | 2014-08-26 | Antibodies |
| EP14755668.2A EP3038643B1 (en) | 2013-08-30 | 2014-08-26 | Antibodies against csf-1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191051T1 true HRP20191051T1 (hr) | 2019-09-06 |
Family
ID=49397073
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231264TT HRP20231264T1 (hr) | 2013-08-30 | 2014-08-26 | Protutijela protiv csf-1r |
| HRP20191051TT HRP20191051T1 (hr) | 2013-08-30 | 2019-06-12 | Antitijela protiv csf-1r |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231264TT HRP20231264T1 (hr) | 2013-08-30 | 2014-08-26 | Protutijela protiv csf-1r |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US9908939B2 (hr) |
| EP (3) | EP3038643B1 (hr) |
| JP (3) | JP6632075B2 (hr) |
| KR (1) | KR102303130B1 (hr) |
| CN (2) | CN112321711A (hr) |
| AR (1) | AR097464A1 (hr) |
| AU (1) | AU2014314304B2 (hr) |
| BR (1) | BR112016004324B1 (hr) |
| CA (1) | CA2922240C (hr) |
| CL (1) | CL2016000438A1 (hr) |
| CY (1) | CY1121964T1 (hr) |
| DK (2) | DK3549599T5 (hr) |
| EA (1) | EA036255B1 (hr) |
| ES (2) | ES2965207T3 (hr) |
| FI (1) | FI3549599T3 (hr) |
| GB (1) | GB201315487D0 (hr) |
| HK (1) | HK1220142A1 (hr) |
| HR (2) | HRP20231264T1 (hr) |
| HU (2) | HUE064437T2 (hr) |
| IL (1) | IL244043B (hr) |
| LT (2) | LT3549599T (hr) |
| MA (2) | MA44922B1 (hr) |
| MX (1) | MX2016002166A (hr) |
| MY (1) | MY172484A (hr) |
| NZ (1) | NZ717399A (hr) |
| PE (2) | PE20160528A1 (hr) |
| PH (1) | PH12016500275B1 (hr) |
| PL (2) | PL3038643T3 (hr) |
| PT (2) | PT3038643T (hr) |
| RS (2) | RS59019B1 (hr) |
| SG (1) | SG11201601151PA (hr) |
| SI (2) | SI3038643T1 (hr) |
| TN (1) | TN2016000067A1 (hr) |
| TR (1) | TR201909478T4 (hr) |
| TW (1) | TWI531582B (hr) |
| UA (1) | UA118354C2 (hr) |
| UY (1) | UY35718A (hr) |
| WO (1) | WO2015028455A1 (hr) |
| ZA (1) | ZA201601437B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| WO2016189045A1 (en) * | 2015-05-27 | 2016-12-01 | Ucb Biopharma Sprl | Method for the treatment of neurological disease |
| WO2016196679A1 (en) * | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
| KR102531889B1 (ko) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | 항-pd-l1 및 il-2 사이토카인 |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| EP3624848A1 (en) * | 2017-05-19 | 2020-03-25 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| GB201803226D0 (en) | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| CN108948198B (zh) * | 2018-07-18 | 2020-09-01 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及其应用 |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| WO2020124039A1 (en) * | 2018-12-13 | 2020-06-18 | Development Center For Biotechnology | Anti-human csf-1r antibody and uses thereof |
| WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
| KR20220117320A (ko) * | 2019-12-24 | 2022-08-23 | 아다젠 (수저우) 리미티드 | 항 csf1r 분자 및 이의 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| SI2188313T1 (en) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | HUMAN C-FMS ANTIGEN TRANSFER PROTEIN |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| CN101970496B (zh) | 2008-03-14 | 2014-04-16 | 特朗斯吉有限公司 | 针对csf-1r的抗体 |
| PL2334705T3 (pl) | 2008-09-26 | 2017-06-30 | Ucb Biopharma Sprl | Produkty biologiczne |
| ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| ES2557454T3 (es) * | 2009-12-10 | 2016-01-26 | F. Hoffmann-La Roche Ag | Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| EP2542587A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| MX336682B (es) | 2010-03-05 | 2016-01-27 | Hoffmann La Roche | Anticuerpos contra csf-1r humanos y usos de los mismos. |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| CN106977603B (zh) * | 2010-05-04 | 2020-11-27 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
-
2013
- 2013-08-30 GB GBGB1315487.7A patent/GB201315487D0/en not_active Ceased
-
2014
- 2014-08-05 TW TW103126815A patent/TWI531582B/zh active
- 2014-08-26 WO PCT/EP2014/068050 patent/WO2015028455A1/en active Application Filing
- 2014-08-26 LT LTEP19171833.7T patent/LT3549599T/lt unknown
- 2014-08-26 DK DK19171833.7T patent/DK3549599T5/da active
- 2014-08-26 KR KR1020167007073A patent/KR102303130B1/ko active IP Right Grant
- 2014-08-26 ES ES19171833T patent/ES2965207T3/es active Active
- 2014-08-26 PE PE2016000313A patent/PE20160528A1/es unknown
- 2014-08-26 SI SI201431235T patent/SI3038643T1/sl unknown
- 2014-08-26 US US14/914,676 patent/US9908939B2/en active Active
- 2014-08-26 MY MYPI2016700624A patent/MY172484A/en unknown
- 2014-08-26 HR HRP20231264TT patent/HRP20231264T1/hr unknown
- 2014-08-26 RS RS20190833A patent/RS59019B1/sr unknown
- 2014-08-26 CA CA2922240A patent/CA2922240C/en active Active
- 2014-08-26 PT PT14755668T patent/PT3038643T/pt unknown
- 2014-08-26 LT LTEP14755668.2T patent/LT3038643T/lt unknown
- 2014-08-26 HU HUE19171833A patent/HUE064437T2/hu unknown
- 2014-08-26 SI SI201432048T patent/SI3549599T1/sl unknown
- 2014-08-26 BR BR112016004324-3A patent/BR112016004324B1/pt active IP Right Grant
- 2014-08-26 ES ES14755668T patent/ES2733735T3/es active Active
- 2014-08-26 PE PE2020000532A patent/PE20201067A1/es unknown
- 2014-08-26 CN CN202011009068.8A patent/CN112321711A/zh active Pending
- 2014-08-26 UA UAA201601175A patent/UA118354C2/uk unknown
- 2014-08-26 EP EP14755668.2A patent/EP3038643B1/en active Active
- 2014-08-26 AU AU2014314304A patent/AU2014314304B2/en active Active
- 2014-08-26 RS RS20230962A patent/RS64784B1/sr unknown
- 2014-08-26 PL PL14755668T patent/PL3038643T3/pl unknown
- 2014-08-26 DK DK14755668.2T patent/DK3038643T3/da active
- 2014-08-26 HU HUE14755668A patent/HUE045672T2/hu unknown
- 2014-08-26 EP EP23192221.2A patent/EP4282881A3/en active Pending
- 2014-08-26 MX MX2016002166A patent/MX2016002166A/es active IP Right Grant
- 2014-08-26 CN CN201480057403.8A patent/CN105658236B/zh active Active
- 2014-08-26 JP JP2016537262A patent/JP6632075B2/ja active Active
- 2014-08-26 FI FIEP19171833.7T patent/FI3549599T3/fi active
- 2014-08-26 PT PT191718337T patent/PT3549599T/pt unknown
- 2014-08-26 PL PL19171833.7T patent/PL3549599T3/pl unknown
- 2014-08-26 NZ NZ717399A patent/NZ717399A/en unknown
- 2014-08-26 EP EP19171833.7A patent/EP3549599B1/en active Active
- 2014-08-26 MA MA44922A patent/MA44922B1/fr unknown
- 2014-08-26 SG SG11201601151PA patent/SG11201601151PA/en unknown
- 2014-08-26 TR TR2019/09478T patent/TR201909478T4/tr unknown
- 2014-08-26 MA MA38930A patent/MA38930A1/fr unknown
- 2014-08-26 TN TN2016000067A patent/TN2016000067A1/en unknown
- 2014-08-26 EA EA201690503A patent/EA036255B1/ru not_active IP Right Cessation
- 2014-08-27 AR ARP140103206A patent/AR097464A1/es unknown
- 2014-08-29 UY UY35718A patent/UY35718A/es not_active Application Discontinuation
-
2016
- 2016-02-09 IL IL244043A patent/IL244043B/en active IP Right Grant
- 2016-02-10 PH PH12016500275A patent/PH12016500275B1/en unknown
- 2016-02-25 CL CL2016000438A patent/CL2016000438A1/es unknown
- 2016-03-02 ZA ZA2016/01437A patent/ZA201601437B/en unknown
- 2016-07-15 HK HK16108335.9A patent/HK1220142A1/zh unknown
-
2018
- 2018-01-30 US US15/883,130 patent/US10421814B2/en active Active
-
2019
- 2019-06-12 HR HRP20191051TT patent/HRP20191051T1/hr unknown
- 2019-07-23 CY CY20191100779T patent/CY1121964T1/el unknown
- 2019-09-13 JP JP2019166697A patent/JP7195237B2/ja active Active
-
2021
- 2021-09-17 JP JP2021152574A patent/JP2022002523A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191051T1 (hr) | Antitijela protiv csf-1r | |
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| RU2015129762A (ru) | ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| HRP20190774T1 (hr) | Kombinacija anti-lag-3 antitijela i anti-pd-1 antitijela za liječenje tumora | |
| JP2020501532A5 (hr) | ||
| JP2016500673A5 (hr) | ||
| HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
| RU2022108079A (ru) | Антитело против garp | |
| RU2017134274A (ru) | Связывающие tslp белки | |
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JP2016053091A5 (hr) | ||
| JP2012116856A5 (hr) | ||
| HRP20191129T1 (hr) | Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora | |
| AR076670A1 (es) | Anticuerpos humanizados especificos de la forma protofibrilar del peptido beta-amiloide. | |
| JP2013056885A5 (hr) | ||
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| HRP20181055T1 (hr) | Antagonisti kv1.3 i postupci upotrebe | |
| MX2014011066A (es) | Moleculas de union novedosas con actividad antitumoral. | |
| JP2015501814A5 (hr) | ||
| HRP20170468T1 (hr) | Bispecifična protutijela protiv baff i protiv il-17 | |
| HRP20211079T1 (hr) | Konstrukcije sirp-alfa varijante i njihove uporabe | |
| HRP20191590T1 (hr) | Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen | |
| JP2013539369A5 (hr) | ||
| JP2014527040A5 (hr) |